Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon
Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon
Novocure从Pharmakon获得新的4亿美元非稀释性债务融资
Use of proceeds to fund working capital needs stemming from Novocure's anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure's convertible notes
使用所得款项为Novocure预计在非小细胞肺癌领域上市所产生的营运资金需求提供资金，并在到期时结算Novocure的可转换票据
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。